Browse

Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer

DC Field Value Language
dc.contributor.authorHong, Yong Sang-
dc.contributor.authorCho, Hyeon Jin-
dc.contributor.authorKim, Sun Young-
dc.contributor.authorJung, Kyung Hae-
dc.contributor.authorChoi, Hyo Seong-
dc.contributor.authorKim, Byung Chang-
dc.contributor.authorKim, Dae Yong-
dc.contributor.authorChang, Hee Jin-
dc.contributor.authorSohn, Dae Kyung-
dc.contributor.authorOh, Jae Hwan-
dc.contributor.authorPark, Ji Won-
dc.date.accessioned2012-06-22T07:27:22Z-
dc.date.available2012-06-22T07:27:22Z-
dc.date.issued2009-07-21-
dc.identifier.citationBMC CANCER; Vol.9 ; 246ko_KR
dc.identifier.issn1471-2407-
dc.identifier.urihttps://hdl.handle.net/10371/77333-
dc.description.abstractBackground: Carbonic anhydrase 9 (CA9) is a marker for hypoxia and acidosis, which is linked to a poor prognosis in human tumors. The purpose of this comparative analysis was to evaluate whether CA9 and VEGF expression are associated with survival outcomes in patients with metastatic colorectal cancer (mCRC) after treatment with bevacizumab as second or later line treatment. Methods: Thirty-one mCRC patients who were treated with bevacizumab-containing chemotherapy as second or later line treatment and who had analyzable tumor paraffin blocks were selected for this study. The planned dose of bevacizumab was 5 mg/kg/2-week. Immunohistochemical (IHC) staining of CA9 and VEGF was performed and their expression was scored by the intensity multiplied by percentage of stained area. Results: The overall response rate was 19.4% and the disease control rate (DCR) was 61.3% with 6 partial responses and 13 cases of stable disease. The DCR was significantly higher in patients with a lower CA9 expression score compared to those with a higher score (80.0% vs. 27.3%, respectively, P = 0.004). The patients with a low CA9 expression score also showed better outcomes with regard to the median progression-free survival (P = 0.028) and overall survival (P = 0.026). However, VEGF expression was not associated with the DCR and survival. Conclusion: Lower degree of CA9 expression was associated with better clinical outcomes in patients with mCRC treated with lower dose bevacizumab-based chemotherapy. Prospective studies are now needed to determine the correlation between CA9 expression and clinical outcomes after bevacizumab treatment, at different doses and in varied settings.ko_KR
dc.language.isoenko_KR
dc.publisherBIOMED CENTRAL LTDko_KR
dc.titleCarbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancerko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor홍용상-
dc.contributor.AlternativeAuthor조현진-
dc.contributor.AlternativeAuthor김선영-
dc.contributor.AlternativeAuthor정경해-
dc.contributor.AlternativeAuthor박지원-
dc.contributor.AlternativeAuthor최효성-
dc.contributor.AlternativeAuthor오재환-
dc.contributor.AlternativeAuthor김병창-
dc.contributor.AlternativeAuthor손대경-
dc.contributor.AlternativeAuthor김대용-
dc.contributor.AlternativeAuthor장희진-
dc.identifier.doi10.1186/1471-2407-9-246-
dc.citation.journaltitleBMC CANCER-
dc.description.citedreferenceReck M, 2009, J CLIN ONCOL, V27, P1227, DOI 10.1200/JCO.2007.14.5466-
dc.description.citedreferenceKarapetis CS, 2008, NEW ENGL J MED, V359, P1757-
dc.description.citedreferenceChoi SW, 2008, HUM PATHOL, V39, P1317, DOI 10.1016/j.humpath.2007.10.026-
dc.description.citedreferenceWinum JY, 2008, MED RES REV, V28, P445, DOI 10.1002/med.20112-
dc.description.citedreferenceGruenberger B, 2008, J CLIN ONCOL, V26, P1830, DOI 10.1200/JCO.2007.13.7679-
dc.description.citedreferenceSelvakumaran M, 2008, BIOCHEM PHARMACOL, V75, P627, DOI 10.1016/j.bcp.2007.09.029-
dc.description.citedreferenceSathornsumetee S, 2008, J CLIN ONCOL, V26, P271, DOI 10.1200/JCO.2007.13.3652-
dc.description.citedreferenceLeibovich BC, 2007, J CLIN ONCOL, V25, P4757, DOI 10.1200/JCO.2007.12.1087-
dc.description.citedreferenceSwietach P, 2007, CANCER METAST REV, V26, P299, DOI 10.1007/s10555-007-9064-0-
dc.description.citedreferenceEmmanouilides C, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-91-
dc.description.citedreferenceGiantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305-
dc.description.citedreferenceLee S, 2007, CANCER SCI, V98, P329, DOI 10.1111/j.1349-7006.2007.00396.x-
dc.description.citedreferenceVredenburgh JJ, 2007, CLIN CANCER RES, V13, P1253, DOI 10.1158/1078-0432.CCR-06-2309-
dc.description.citedreferenceBir A, 2007, ONCOLOGY-BASEL, V72, P4, DOI 10.1159/000110546-
dc.description.citedreferenceGROTHEY E, 2007, CLIN COLORECTAL CANC, V6, P621-
dc.description.citedreferenceBrennan DJ, 2006, CLIN CANCER RES, V12, P6421, DOI 10.1158/1078-0432.CCR-06-0480-
dc.description.citedreferenceGiantonio BJ, 2006, ANN ONCOL, V17, P1399, DOI 10.1093/annonc/mdl161-
dc.description.citedreferenceChen HX, 2006, J CLIN ONCOL, V24, P3354, DOI 10.1200/JCO.2005.05.1573-
dc.description.citedreferenceJubb AM, 2006, J CLIN ONCOL, V24, P217, DOI 10.1200/JCO.2005.01.5388-
dc.description.citedreferenceHurwitz HI, 2005, J CLIN ONCOL, V23, P3502-
dc.description.citedreferenceAtkins M, 2005, CLIN CANCER RES, V11, P3714-
dc.description.citedreferenceRobertson N, 2004, CANCER RES, V64, P6160-
dc.description.citedreferenceHurwitz H, 2004, NEW ENGL J MED, V350, P2335-
dc.description.citedreferenceJohnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022-
dc.description.citedreferenceTournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113-
dc.description.citedreferenceYang JC, 2003, NEW ENGL J MED, V349, P427-
dc.description.citedreferencePotter CPS, 2003, BRIT J CANCER, V89, P2, DOI 10.1038/sj.bjc.6600936-
dc.description.citedreferenceBui MHT, 2003, CLIN CANCER RES, V9, P802-
dc.description.citedreferenceKabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066-
dc.description.citedreferenceGiatromanolaki A, 2001, CANCER RES, V61, P7992-
dc.description.citedreferencede Gramont A, 2000, J CLIN ONCOL, V18, P2938-
dc.description.citedreferenceLee JC, 2000, EUR J CANCER, V36, P748-
dc.description.citedreferenceDouillard JY, 2000, LANCET, V355, P1041-
dc.description.citedreferenceTherasse P, 2000, J NATL CANCER I, V92, P205-
dc.description.citedreferenceUemura H, 1999, BRIT J CANCER, V81, P741-
dc.description.citedreferenceFerrara N, 1999, J MOL MED-JMM, V77, P527-
dc.description.citedreferenceSaarnio J, 1998, AM J PATHOL, V153, P279-
dc.description.citedreferencePresta LG, 1997, CANCER RES, V57, P4593-
dc.description.citedreferenceRelf M, 1997, CANCER RES, V57, P963-
dc.description.citedreferencedeGramont A, 1997, J CLIN ONCOL, V15, P808-
dc.description.citedreferenceBROOK J, 1995, J CLIN ONCOL, V13, P1830-
dc.description.citedreferencePASTOREKOVA S, 1992, VIROLOGY, V187, P620-
dc.description.tc4-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse